Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 13/20 | 0.79 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350700 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL4356542 | 0.90 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL4356546 | 0.90 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL2578946 | 0.90 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL1037900 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL2575165 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL11910325 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL2583297 | 0.89 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL2576286 | 0.89 | SLC5A2 (0.80) | SLC5A2SLC5A1 | |
| SCHEMBL10822009 | 0.89 | SLC5A2 (0.79) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | claimed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | claimed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | claimed |
| EP-3976053-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | Avolynt (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20170333353-A1 | BILAYER TABLET FORMULATIONS | BRISTOL-MEYERS SQUIBB COMPANY | 2017-11-23 | — | — | US | disclosed |
| US-9616028-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2017-04-11 | — | — | US | disclosed |
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-20150238421-A1 | Bilayer Tablet Formulations | ASTRAZENECA AB (SE) | 2015-08-27 | — | — | US | disclosed |
| US-9050258-B2 | Bilayer tablet formulations | ASTRAZENECA AB (SE) | 2015-06-09 | — | — | US | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20140371162-A1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-18 | — | — | US | disclosed |
| US-6872706-B2 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-03-29 | — | — | US | disclosed |
| US-20050065098-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. | 2005-03-24 | — | — | US | disclosed |
| CN-1177857-C | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the prepararation of the derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-12-01 | — | — | CN | disclosed |
| US-20040053855-A1 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | KISSEI PHARMACEUTICAL CO & LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040018998-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| CN-1466590-A | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | ����ҩƷ��ҵ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| EP-1329456-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-07-23 | — | — | EP | disclosed |
| CN-1418219-A | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the prepararation of the derivatives | KISSEI PHARMACEUTICAL (JP) | 2003-05-14 | — | — | CN | disclosed |
| EP-1270584-A1 | GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333353-A1 | BILAYER TABLET FORMULATIONS | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885EPHX2 2505/4885 |
| US-20040053855-A1 | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885EPHX2 1752/4885 |
| US-20150238421-A1 | Bilayer Tablet Formulations | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885SLC5A1 2/4885EPHX2 2505/4885 |
| US-20140371162-A1 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS | DPP4, SLC5A1, GLP1R | SLC5A2 5/4885SLC5A1 2/4885EPHX2 3927/4885 |
| US-20050065098-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885EPHX2 1507/4885 |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | SLC5A2 3/4885SLC5A1 1/4885EPHX2 2031/4885 |
| US-20040018998-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885EPHX2 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.